Efficacy of zilucoplan in patients with generalised myasthenia gravis who have not previously received immunoglobulin or plasma exchange: A subgroup analysis from the Phase 3 RAISE study

Summary of Research:  Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis:  2-year Results from Two Phase 3 Studies

Effect of Bimekizumab on Patient-Reported Outcomes and Work Productivity in Patients With Psoriatic Arthritis: 1-Year Results From 2 Phase III Studies

Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the Be Bright open-label extension trial

Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies

Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies

Risk of exacerbation and level of healthcare resource utilization in myasthenia 

Rozanolixizumab improved symptoms in people with generalised myasthenia gravis in the MycarinG clinical study: a Plain Language Summary of Publication

Daily self-injection of zilucoplan improved symptoms in people with generalized myasthenia gravis in the RAISE clinical study: a Plain Language Summary of Publication

Hidradenitis Suppurativa Symptom Daily Diary (HSSDD) and Questionnaire (HSSQ): Psychometric Validation and Interpretation Threshold Derivation Using Phase 3 Study Data